Selected publications

Bioorganic and Medicinal Chemistry Group

Publications - since 2016

2024

V. Kerestes, J. Kubes, L. Applova, P. Kollarova, O. Lencova-Popelova, I. Melnikova, G. Karabanovich, M. M. Khazeem, H. Bavlovic-Piskackova, P. Sterbova-Kovarikova, C. A. Austin, J. Roh, M. Sterba, T. Simunek, A. Jirkovska. Exploring the effects of topoisomerase II inhibitor XK469 on anthracycline cardiotoxicity and DNA damage. Tox. Sci. 2024. 198 (2), 288–302. (IF₂₀₂₂= 3.8) (Q_AIS1)
G. Karabanovich, V. Fabiánová, A. Vocat, J. Dušek, L. Valášková, J. Stolaříková, R. R. A. Kitson, P. Pávek, K. Vávrová, K. Djaout, K. Mikušová, A. R. Baulard, S. T. Cole, J. Korduláková, J. Roh. Both nitro groups are essential for high antitubercular activity of 3,5-dinitrobenzylsulfanyl tetrazoles and 1,3,4-oxadiazoles through the deazaflavin-dependent nitroreductase activation pathway. J. Med. Chem. 2024, 67, 81-109. (IF₂₀₂₂ = 7.3) (D_AIS1)

2023

V. Finger, T. Kucera, R. Kafkova, L. Muckova, R. Dolezal, J. Kubes, M. Novak, L. Prchal, L. Lakatos, M. Andrs, M. Hympanova, J. Marek, M. Kufa, V. Spiwok, O. Soukup, E. Mezeiova, J. Janousek, L. Nevosadova, M. Benkova, R.R.A. Kitson, M. Kratky, S. Bősze, K. Mikusova, R. Hartkoorn, J. Roh, J. Korabecny, 2,6-Disubstituted 7-(naphthalen-2-ylmethyl)-7H-purines as a new class of potent antitubercular agents inhibiting DprE1, Eur. J. Med. Chem. 2023, 258, 115611. (IF₂₀₂₂ = 6.7) (Q_AIS1)
P. Hatokova, V. Sestak, H. Bavlovic Piskackova, I. Melnikova, J. Roh, P. Sterbova-Kovarikova. The UHPLC-UV method applied for the forced degradation study of ixazomib and HRMS identification of its degradation products. J. Pharm. Biomed. Anal. 2023, 225, 115220. (IF₂₀₂₁ = 3.571) (Q_AIS2, 3)
V. Finger, M. Kufa, O. Soukup, D. Castagnolo, J. Roh, J. Korabecny. Pyrimidine derivatives with antitubercular activity. Eur. J. Med. Chem. 2023, 15(246), 114946. (IF₂₀₂₂ = 6.7) (Q_AIS1)

2022

M. Kopecna, M. Machacek, J. Roh, K. Vavrova. Proline, hydroxyproline, and pyrrolidone carboxylic acid derivatives as highly efficient but reversible transdermal permeation enhancers. Sci. Rep. 2022, 12(1), 19495. (IF₂₀₂₁ = 4.997) (Q_AIS2)
P. Haskova, L. Applova, H. Jansova, P. Homola, K. J. Franz, K. Vavrova, J. Roh, T. Simunek. Examination of diverse iron-chelating agents for the protection of differentiated PC12 cells against oxidative injury induced by 6-hydroxydopamine and dopamine. Sci. Rep. 2022, 12, 9765. (IF₂₀₂₁ = 4.997) (Q_AIS2)
V. Finger, M. Kufa, O. Soukup, D. Castagnolo, J. Roh, J. Korabecny. Pyrimidine derivatives with antitubercular activity. Eur. J. Med. Chem. 2022, 15(246), 114946. (IF₂₀₂₁ = 7.088) (Q_AIS1)

2021

E. Jirkovský, A. Jirkovská, H. Bavlovič-Piskáčková, V. Skalická, Z. Pokorná, G. Karabanovich, P. Kollárová-Brázdová, J. Kubeš, O. Lenčová-Popelová, Y. Mazurová, M. Adamcová, A. R. Lyon, J. Roh, T. Šimůnek, P. Štěrbová-Kovaříková, M. Štěrba. Clinically Translatable Prevention of Anthracycline Cardiotoxicity by Dexrazoxane Is Mediated by Topoisomerase II Beta and Not Metal Chelation. Circ Heart Fail. 2021;14: e008209. (IF₂₀₂₁ = 10.447) (D_AIS1)
P. Kollárová-Brázdová, O. Lencova-Popelova, G. Karabanovich; J. Kocúrová-Lengvarská, J. Kubes, N. Váňová, Y. Mazurova, M. Adamcova, A. Jirkovska, M. Holečková, T. Šimůnek, P. Štěrbová-Kovaříková, J. Roh, M. Štěrba. Prodrug of ICRF-193 provides promising protective effects against chronic anthracycline cardiotoxicity on a rabbit model in vivo. Clin. Sci. 2021. https://doi.org/10.1042/CS20210311. (IF₂₀₂₀= 6.124) (Q_AIS1)
A. Jirkovská, G. Karabanovich, J. Kubeš, V. Skalická, I. Melnikova, J. Korábečný, T. Kučera, E. Jirkovský, L. Nováková, H. Bavlovič Piskáčková, J. Škoda, M. Štěrba, C. A. Austin, T. Šimůnek, J. Roh. Structure−Activity Relationship Study of Dexrazoxane Analogues Reveals ICRF-193 as the Most Potent Bisdioxopiperazine against Anthracycline Toxicity to Cardiomyocytes Due to Its Strong Topoisomerase IIβ Interactions. J. Med. Chem. 2021, 64, 3997-4019. (IF₂₀₂₀ = 7.446) (D_AIS1)
H. Bavlovič Piskáčková, H. Jansová, J. Kubeš, G. Karabanovich, N. Váňová, P. Kollárová-Brázdová, I. Melnikova, A. Jirkovská, O. Lenčová-Popelová, J. Chládek, J. Roh, T. Šimůnek, M. Štěrba, P. Štěrbová-Kovaříková. Development of water-soluble prodrugs of the bisdioxopiperazine topoisomerase IIβ inhibitor ICRF 193 as potential cardioprotective agents against anthracycline cardiotoxicity. Scientific Reports. 2021 11, 4456. (IF₂₀₂₀ = 4.379) (Q_AIS1)

N. Monakhova, J. Kordulakova, A. Vocat, A. Egorova, A. Lepioshkin, E. G. Salina, J. Nosek, E. Repkova, J. Zemanova, H. Jurdakova, R. Gorova, J. Roh, G. Degiacomi, J. C. Sammartino, M. R. Pasca, S. T. Cole, K. Mikusova, V. Makarov. Design and Synthesis of Pyrano[3,2-b]indolones Showing Antimycobacterial Activity. ACS Infect. Dis. 2021, 7(1), 88-100. (IF₂₀₁₉ = 5.084) (D_AIS1)
Krátký M., Konečná K., Brokešová K., Maixnerová J., Trejtnar F., Vinšová J. Optimizing the structure of (salicylideneamino)benzoic acids: Towards selective antifungal and anti-staphylococcal agents, Eur. J. Pharm. Sci. 2021, 159, 105732 [ISSN 0928-0987, IF₂₀₁₉ = 3.616]. https://doi.org.10.1016/j.ejps.2021.105732
Y.Sheena Mary, Y.Shyma Mary, Krátký M., Vinsova J., Baraldi C., Gamberini M.C. Concentration dependent SERS, DFT and molecular docking studies of a ureido derivative with antitubercular properties. Spectrochim. Acta A 2021, 249, 119329 [ISSN 1386-1425, IF₂₀₁₉= 3.232]. https://doi.org/10.1016/j.saa.2020.119329
Y. Sheena Mary, Y. Shyma Mary, Krátký M., Vinsova J., Baraldi C., Gamberini M.C. DFT, SERS-concentration and solvent dependent and docking studies of a bioactive benzenesulfonamide derivative. J. Mol. Struct. 2021, 1228 129680. [ISSN 0022-2860, IF₂₀₁₉= 2.463]. https://doi.org/10.1016/j.molstruc.2020.129680
Gamberinia M. C., Y.Shyma Mary, Y.Sheena Mary, Krátký M., Vinsova J., Baraldi C. Spectroscopic investigations, concentration dependent SERS, and molecular docking studies of a benzoic acid derivative. Spectrochim. Acta A 2021, 248, 119265 [ISSN 1386-1425, IF₂₀₁₉= 3.232]. https://doi.org/10.1016/j.saa.2020.119265

2020

P. Kollárová-Brázdová, A. Jirkovská, G. Karabanovich, Z. Pokorná, H. Bavlovič Piskáčková, E. Jirkovský, J. Kubeš, O. Lenčová-Popelová, Y. Mazurová, M. Adamcová, V. Skalická, P. Štěrbová-Kovaříková, J. Roh, T. Šimůnek and M. Štěrba. Investigation of Structure-Activity Relationships of Dexrazoxane Analogs Reveals Topoisomerase IIβ Interaction as a Prerequisite for Effective Protection against Anthracycline Cardiotoxicity. Journal of Pharmacology and Experimental Therapeutics 2020, 373(3), 402-415. (IF₂₀₁₉ = 3.561) (Q2)
Krátký M., Baranyai Z., Štěpánková Š., Svrčková K., Švarcová M., Stolaříková J., Horváth L., Bősze S., Vinšová J. N-Alkyl-2-[4-(trifluoromethyl)benzoyl]hydrazine-1- carboxamides and Their Analogues: Synthesis and Multitarget Biological Activity. Molecules 2020, 25, 2268; https.//doi.org/10.3390/molecules25102268. [ISSN 1420-3049, IF₂₀₁₉ = 3.267].
Ambrożkiewicz W., Kučerová-Chlupáčová M., Janďourek O., Konečná K., Paterová P., Bárta P., Vinšová J., Doležal M., Zitko J. 5-Alkylamino-N-Phenylpyrazine-2-Carboxamides: Design, Preparation, And Antimycobacterial Evaluation. Molecules 2020, 25, 1561; https://doi.org/10.3390/molecules25071561 [ISSN 1420-3049, IF₂₀₁₉ = 3.267].
Krátký M., Konečná K., Janoušek J., Brablíková M., Janďourek O., Trejtnar F., Stolaříková J., Vinšová J. 4-Aminobenzoic acid derivatives: Converting folate precursor to antimicrobial and cytotoxic agents. Biomolecules 2020, 10, 9, 1-21. doi:10.3390/biom10010009. [IF₂₀₁₉= 4,082].
Krátký M., Jaklová K., Štěpánková Š., Svrčková K., Pflégr V., Vinšová J. N-[3,5-Bis(trifluoromethyl)phenyl]-5-bromo-2-hydroxybenzamide Analogues: Novel Acetyl- and Butyrylcholinesterase Inhibitors. Curr. Top. Med. Chem. 2020, 20(23), 2094-2105. https://doi.org/10.2174/1568026620666200819154722 [IF₂₀₁₉= 3,218]
Krátký M., Štěpánková Š., Brablíková M., Svrčková K. Švarcová M., Vinšová J. Novel Iodinated Hydrazide-hydrazones and their Analogues as Acetyl- and Butyrylcholinesterase Inhibitors. Curr. Top. Med. Chem. 2020, 20, (23), 2106-2117. https://doi.org/10.2174/1568026620666200819155503 [IF₂₀₁₉= 3,218].

2019

P. Reimerova, A. Jirkovska, H. Piskackova, G. Karabanovich, J. Roh, T. Simunek, P. Sterbova-Kovarikova. UHPLC-MS/MS method for analysis of sobuzoxane, its active form ICRF-154 and metabolite EDTA-diamide and its application to bioactivation study. Sci. Rep. 2019, 9, Art. No. 4524. (IF₂₀₁₉= 3.998) (Q1)
P. Reimerova; J. Stariat, H. Piskackova, H. Jansova, J. Roh, D.S. Kalinowski, M. Machacek, T. Simunek, D. R. Richardson, P. Sterbova-Kovarikova. Novel SPME fibers based on a plastic support for determination of plasma protein binding of thiosemicarbazone metal chelators: a case example of DpC, an anti-cancer drug that entered clinical trials. Anal. Bioanal. Chem. 2019, 411(11), 2383-2394. (IF₂₀₁₉= 3.637) (Q1)
G. Karabanovich, J. Dušek, K. Savková, O. Pavliš, I. Pávková, J. Korabecny, T. Kučera, H. Kočová Vlčková, S. Huszár, Z. Konyariková, K. Konečná, O. Jandourek, J. Stolaříková, J. Korduláková, K. Vávrová, P. Pavek, V. Klimešová, A. Hrabalek, K. Mikušová, J. Roh. Development of 3,5-Dinitrophenyl-Containing 1,2,4-Triazoles and their Trifluoromethyl Analogues as Highly Efficient Antitubercular Agents Inhibiting Decaprenylphosphoryl-β-D-ribofuranose 2′-Oxidase. J. Med. Chem. 2019,62, 8115-8139. (IF₂₀₁₉ = 6.205) (Q1)
Krátký M., Štěpánková Š., Houngbedji Neto-Honorius, Vosátka R., Vorčáková K., Vinšová J. 2-Hydroxy-N-phenylbenzamides and their Esters Inhibit Acetylcholinesterase and Butyrylcholinesterase. Biomolecules 2019, 9, 698; doi:10.3390/biom9110698, [IF₂₀₁₉= 4,082]]
Krátký M., Janďourek O., Baranyai Zs., Novotná E., Stolaříková J., Bősze S., Vinšová J. Phenolic N-monosubstituted carbamates: Antitubercular and toxicity evaluation of multi-targeting compounds. Eur. J. Med. Chem. 2019, 181, 111578 [ISSN 0223-5234, IF₂₀₁₉= 5.572].

2018

H. Jansová, J. Kubeš, P. Reimerová, P. Štěrbová-Kovaříková, J. Roh, and T. Šimůnek. 2,6-Dihydroxybenzaldehyde Analogues of the Iron Chelator Salicylaldehyde Isonicotinoyl Hydrazone: Increased Hydrolytic Stability and Cytoprotective Activity against Oxidative Stress. Chem. Res. Toxicol., 2018, 31 (11), 1151–1163. (IF₂₀₁₇ = 3.432) (Q1)
E. Jirkovský, A. Jirkovská, J. Bureš, J. Chládek, O. Lenčová, J. Stariat, Z. Pokorná, G. Karabanovich, J. Roh, P. Brázdová, T. Šimůnek, P. Kovaříková, M. Štěrba. Pharmacokinetics of the cardioprotective drug dexrazoxane and its active metabolite ADR-925 with focus on cardiomyocytes and the heart. Journal of Pharmacology and Experimental Therapeutics. 2018, 364 (3), 433-446. (IF₂₀₁₇ = 3.706) (Q1)

Krátký M., Vorčáková K., Vinšová J., Štěpánková Š. Investigation of salicylanilide and 4-chlorophenol-based N-monosubstituted carbamates as potential inhibitors of acetyl- and butyrylcholinesterase, Bioorg. Chem. 2018, 80, 668-673 [ISSN 0968-0896, IF₂₀₁₇ = 3.929].
Zitko J., Janďourek O., Paterová P., Navrátilová L., Kuneš J., Vinšová J., Doležal M. Design, synthesis and antimycobacterial activity of hybrid molecules combining pyrazinamide with 4-phenylthiazol-2-amine scaffold. MedChemComm. 2018. 9(4), 685-696. [ISSN 2040-2503], IF₂₀₁₇= 2.342, doi: http://dx.doi.org/10.1039/C8MD00056E
Pospíšilová Š., Michnová H., Pauk K., Vinšová J., Imramovský A., Čížek A., Jampílek J. In vitro activity of salicylamide derivatives against vancomycin-resistant enterococci. Bioorg. Med. Chem. Letters 2018, 28, 2184-2188. [ISSN 0960-894X, IF₂₀₁₇ = 2.442]
Vosátka R., Krátký M., Švarcová M., Janoušek J., Stolaříková J., Madacki J., Husza S., Mikušová K., Korduláková J.,Trejtnar F., Vinšová J. New lipophilic isoniazid derivatives and their 1,3,4-oxadiazole analogues: Synthesis, antimycobacterial activity and investigation of their mechanism of action. Eur. J. Med. Chem. 2018,151, 824-835. [ISSN 0223-5234, IF₂₀₁₇ = 4,816]
Vosátka R., Krátký M., Vinšová J. Triclosan and its derivatives as antimycobacterial active agents Eur. J. Pharm. Sci. 2018, 114, 318–331. [ISSN 0928-0987, IF₂₀₁₆ = 3.466]. doi.org/10.1016/j.ejps.2017.12.013

2017

J. Bureš, A. Jirkovská, V. Šesták, H. Jansová, G. Karabanovich, J. Roh, M. Štěrba, T. Šimůnek, P. Kovaříková. Investigation of novel dexrazoxane analogue JR-311 shows significant cardioprotective effects through topoisomerase IIbeta but not its iron chelating metabolite. Toxicology 2017, 392, 1-10.
G. Karabanovich, J. Němeček, L. Valášková, A. Carazo, K. Konečná, J. Stolaříková, A. Hrabálek, O. Pavliš, P. Pávek, K. Vávrová, J. Roh, V. Klimešová. S-Substituted 3,5-Dinitrophenyl 1,3,4-Oxadiazole-2-thiols and Tetrazole-5-thiols as Highly Efficient Antitubercular Agents. Eur. J. Med. Chem. 2017, 126, 369-383. (IF₂₀₁₆ = 4.519) (Q1)
J. Němeček, P. Sychra, M. Macháček, M. Benková, G. Karabanovich, K. Konečná, V. Kavková, J. Stolaříková, A. Hrabálek, K. Vávrová, O. Soukup, J. Roh, V. Klimešová. Structure-activity relationship studies on 3,5-dinitrophenyl tetrazoles as antitubercular agents. Eur. J. Med. Chem. 2017, 130, 419–432. (IF₂₀₁₆ = 4.519) (Q1)
J. Roh, G. Karabanovich, H. Vlčková, A. Carazo, J. Němeček, P. Sychra, L. Valášková, O. Pavliš, J. Stolaříková, V. Klimešová, K. Vávrová, P. Pávek, A. Hrabálek. Development of Water-Soluble 3,5-Dinitrophenyl Tetrazole and Oxadiazole Antitubercular Agents. Bioorg. Med. Chem. 2017, 25, 5468–5476.
I. Melnikova, J. Roh, J. Kuneš, T. Artamonova, Y. Zevatskii, L. Myznikov. Non-catalyzed addition of heterocyclic thiols and 5-substituted-1H-tetrazoles to vinyl ethers. Tetrahedron Lett. 2017, 58, 3842–3845.

Krátký M., Bősze S., Baranyai Zs., Stolaříková J., Vinšová J. Synthesis and biological evolution of hydrazones derived from 4-(trifluoromethyl)benzohydrazide. Bioorg. Med. Chem. Lett. 2017, 27,5185-5189. [ISSN 0960-894X, IF₂₀₁₆ = 2.454]. doi: 10.1016/j.bmcl.2017.10.050
Krátký M., Dzurková M., Janoušek O., Konečná K., Trejtnar F., Stolaříková J., Vinšová J. Sulfadiazine Salicylaldehyde-Based Schiff Bases: Synthesis, Antimicrobial Activity and Cytotoxicity. Molecules 2017, 22, 1573 [ISSN 1420-3049, IF₂₀₁₆ = 2.861]. doi:10.3390/molecules22091573
Krátký M., Stolaříková J., Vinšová J. Antimicrobial activity of rhodanine-3-acetic acid derivatives. Bioorg. Med. Chem. 2017, 25(6), 1839–1845 [ISSN 0968-0896, IF₂₀₁₆ = 2.930]. https://doi.org/10.1016/j.bmc.2017.01.045
Baranyai Zs, Krátký M., Vosátka M., Szabó N., Senoner Sz., Dávid S., Stolaříková J., Vinšová J., Bősze S. In vitro biological evaluation of new antimycobacterial salicylanilide-tuftsin conjugates. Europ. J. Med. Chem. 2017, 133, 152-173 [ISSN 0223-5234, IF₂₀₁₆ = 4.519]. https://doi.org/10.1016/j.ejmech.2017.03.047
Krátký M., Stolaříková J., Vinšová J. Novel Sulfamethoxazole Ureas and Oxalamides as Potential Antimicobacterial Agents. Molecules 2017, 22(4), 535 [ISSN 1420-3049, IF₂₀₁₆ = 2.861]. doi:10.3390/molecules22040535
Krátký M., Vinšová J., Štěpánková Š., Vorčáková K., Navrátilová L., Trejtnar F., Stolaříková J. Novel Fluorophenylalanine Derivatives: Synthesis and Investigation of Their Biological Activity. Bioorganic Chemistry 2017, 71, 244 - 256 [ISSN: 0045-2068, IF₂₀₁₆ = 3.402]. https://doi.org/10.1016/j.bioorg.2017.02.010
Paraskevopoulos G., Monteiro S., Vosátka R., Krátký M., Navrátilová L., Trejtnar F., Stolaříková J., Vinšová J. Novel salicylanilides from 4,5-dihalogenated salicylic acids: Synthesis, antimicrobial activity and cytotoxicity. Bioorg. Med. Chem. 2017, 25(4), 1524-1532 [ISSN 0968-0896, IF₂₀₁₆ = 2.930]. http://dx.doi.org/10.1016/j.bmc.2017.01.016

2016

V. Sestak, J. Stariat, J. Cermanova, E. Potuckova, J. Chladek, J. Roh, J. Bures, H. Jansova, P. Prusa, M. Sterba, S. Micuda, T. Simunek, D. S. Kalinowski, D. R. Richardson, P. Kovarikova. Novel and potent anti-tumor and anti-metastatic di-2-pyridylketone thiosemicarbazones demonstrate marked differences in pharmacology between the first and second generation lead agents. Oncotarget, 2016, 6 (40), 42411-42428. (IF₂₀₁₆= 5.168) (Q1)
V. Sestak , J. Roh, L. Klepalova, P. Kovarikova. A UHPLC-UV-QTOF Study on the Stability of Carfilzomib, A Novel Proteasome Inhibitor. Journal of Pharmaceutical and Biomedical Analysis, 2016, 124, 365–373. (IF₂₀₁₆ = 3.255) (Q1)
H. Jansová, J. Bureš, M. Macháček, P. Hašková, A. Jirkovská, J. Roh, Q. Wang, K. J. Franz, P. Kovaříková, T. Šimůnek. Characterization of cytoprotective and toxic properties of iron chelator SIH, prochelator BSIH and their degradation products. Toxicology, 2016, 350, 15–24. (IF₂₀₁₆ = 3.582) (Q1)
J. Roh, G. Karabanovich, V. Novakova, T. Šimůnek, K. Vávrová. Large-scale synthesis of piperazine-2,6-dione and its use in the synthesis of dexrazoxane analogues. Synthesis. 2016, 48, 4580-4588. (IF₂₀₁₆ = 2.650)
G. Karabanovich, J. Zemanová, T. Smutný, R. Székely, M. Šarkan, I. Centárová, A. Vocat, I. Pávková, P. Čonka, J. Němeček, J. Stolaříková, M. Vejsová, K. Vávrová, V. Klimešová, A. Hrabálek, P. Pávek, S. T. Cole, K. Mikušová, J. Roh. Development of 3,5-Dinitrobenzylsulfanyl-1,3,4-Oxadiazoles and Thiadiazoles as Selective Antitubercular Agents Active Against Replicating and Nonreplicating Mycobacterium tuberculosis. J. Med. Chem. 2016, 59, 2362−2380. (IF₂₀₁₆ = 6.259) (Q1)
Krátký M., Štěpánková Š., Vorčáková K., Vinšová J. Synthesis and in vitro evaluation of novel rhodanine derivatives as potential cholinesterase inhibitors. Bioorganic Chemistry 2016, 68, 23-29 [ISSN 0045-2068, IF₂₀₁₆ = 3.231].
Kozic J., Novák Z., Římal V., Profant V., Kuneš J., Vinšová J. Conformations, equilibrium thermodynamics and rotational barriers of secondary thiobenzanilides. Tetrahedron, 2016, 72, 2072-2083 [ISSN: 0040-4020, IF₂₀₁₆ = 2.651]. doi:10.1016/j.tet.2016.02.035
Krátký M., Vinšová J. Salicylanilide N-monosubstituted carbamates: Synthesis and in vitro antimicrobial activity. Bioorg. Med. Chem. 2016, 24(6), 1322-1330. http://dx.doi.org/10.1016/j.bmc.2016.02.004 [ISSN 0968-0896, IF₂₀₁₅₆= 2.930].
Krátký M., Štěpánková Š., Vorčáková K., Švarcová M, Vinšová J. Novel Cholinesterases Inhibitors Based on O-Aromatic N,N-Disubstituted Carbamates and Thiocarbamate, Molecules, 2016, 21, 191-201. [ISSN 1420-3049, IF₂₀₁₆ = 2.861].
Krátký M., Vinšová J. Sulphur-Containing Heterocycles as Antimycobacterial Agents: Recent Advances in Thiophene and Thiadiazole Derivatives, Current Topics in Medicinal Chemistry, 2016, 16(26), 2921-2952 [ISSN 1389-4501, IF₂₀₁₆ = 2.561]. DOI: 10.2174/1568026616666160506131118